 <h1>Cangrelor Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to cangrelor: intravenous powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, cangrelor may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking cangrelor:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain or swelling</li>
<li>back pain</li>
<li>black, tarry stools</li>
<li>blood in the eyes</li>
<li>blood in the urine</li>
<li>bruising or purple areas on the skin</li>
<li>coughing up blood</li>
<li>decreased alertness</li>
<li>dizziness</li>
<li>headache</li>
<li>joint pain or swelling</li>
<li>nosebleeds</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Difficult or labored breathing</li>
<li>tightness in the chest</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Cough</li>
<li>difficulty with swallowing</li>
<li>fast heartbeat</li>
<li>hives, itching, or rash</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>noisy breathing</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cangrelor: intravenous powder for injection</i></p><h3>General</h3><p>The most common adverse reaction was bleeding.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Any Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) bleeding (15.5%), mild GUSTO bleeding (14.9%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Severe/life-threatening GUSTO bleeding, moderate GUSTO bleeding, any Thrombolysis in Myocardial Infarction (TIMI) bleeding, major TIMI bleeding, minor TIMI bleeding</p>
<p><b>Frequency not reported</b>: Coronary artery dissection, coronary artery perforation<sup>[Ref]</sup></p><p>Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) bleeding definitions:</p>
<p>-Severe/life-threatening GUSTO bleeding: Intracranial hemorrhage or bleeding resulting in substantial hemodynamic compromise requiring treatment.</p>
<p>-Moderate GUSTO bleeding: Bleeding requiring blood transfusion but not resulting in hemodynamic compromise.</p>
<p>-Mild GUSTO bleeding: All other bleeding not included in severe or moderate.</p>
<p></p>
<p>Thrombolysis in Myocardial Infarction (TIMI) bleeding definitions:</p>
<p>-Major TIMI bleeding: Any intracranial hemorrhage or any overt bleeding associated with a reduction in hemoglobin of at least 5 g/dL (if hemoglobin is not available, an absolute reduction in hematocrit of 15% or more).</p>
<p>-Minor TIMI bleeding: Any overt sign of bleeding (including observation by imaging techniques) associated with a reduction in hemoglobin of 3 to less than 5 g/dL (if hemoglobin is not available, an absolute reduction in hematocrit of 9% to less than 15%).<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea</p>
<p><b>Frequency not reported</b>: Bronchospasm, stridor<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Worsening renal function in patients with CrCl less than 30 mL/min<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Rare</b> (less than 0.1%): Hypersensitivity</p>
<p><b>Frequency not reported</b>: Anaphylactic reactions, anaphylactic shock<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Angioedema<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Kengreal (cangrelor)." The Medicines Company, Parsippany, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about cangrelor</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: platelet aggregation inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Kengreal</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Percutaneous Coronary Intervention</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cangrelor: intravenous powder for injection</i></p><h3>General</h3><p>The most common adverse reaction was bleeding.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Any Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) bleeding (15.5%), mild GUSTO bleeding (14.9%)</p><p><b>Uncommon</b> (0.1% to 1%): Severe/life-threatening GUSTO bleeding, moderate GUSTO bleeding, any Thrombolysis in Myocardial Infarction (TIMI) bleeding, major TIMI bleeding, minor TIMI bleeding</p><p><b>Frequency not reported</b>: Coronary artery dissection, coronary artery perforation<sup>[Ref]</sup></p><p>Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) bleeding definitions:</p><p>-Severe/life-threatening GUSTO bleeding: Intracranial hemorrhage or bleeding resulting in substantial hemodynamic compromise requiring treatment.</p><p>-Moderate GUSTO bleeding: Bleeding requiring blood transfusion but not resulting in hemodynamic compromise.</p><p>-Mild GUSTO bleeding: All other bleeding not included in severe or moderate.</p><p></p><p>Thrombolysis in Myocardial Infarction (TIMI) bleeding definitions:</p><p>-Major TIMI bleeding: Any intracranial hemorrhage or any overt bleeding associated with a reduction in hemoglobin of at least 5 g/dL (if hemoglobin is not available, an absolute reduction in hematocrit of 15% or more).</p><p>-Minor TIMI bleeding: Any overt sign of bleeding (including observation by imaging techniques) associated with a reduction in hemoglobin of 3 to less than 5 g/dL (if hemoglobin is not available, an absolute reduction in hematocrit of 9% to less than 15%).<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea</p><p><b>Frequency not reported</b>: Bronchospasm, stridor<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Worsening renal function in patients with CrCl less than 30 mL/min<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Rare</b> (less than 0.1%): Hypersensitivity</p><p><b>Frequency not reported</b>: Anaphylactic reactions, anaphylactic shock<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Angioedema<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Kengreal (cangrelor)." The Medicines Company, Parsippany, NJ. </p><h2>More about cangrelor</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: platelet aggregation inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Percutaneous Coronary Intervention</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>